Literature DB >> 12643343

Review of the newer antiepileptic drugs.

Angel Tidwell1, Melanie Swims.   

Abstract

This review article discusses the newer anti-epileptic drugs gabapentin, lamotrigine, tiagabine, topiramate, levetiracetam, oxcarbazepine, and zonisamide. Emphasis is given to FDA-approved indications and place in therapy. The mechanisms of action and pharmacokinetics of each drug is provided and the most common adverse effects are reviewed. Clinical studies leading to FDA approval are discussed. Practical points on proper dosing and monitoring are stressed, and drug interactions are also included.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12643343

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  3 in total

1.  Topiramate therapy for symptomatic trigeminal neuralgia.

Authors:  A Siniscalchi; L Gallelli; D Scornaienghi; F Mancuso; G De Sarro
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

2.  Effects of oxcarbazepine on monoamines content in hippocampus and head and body shakes and sleep patterns in kainic acid-treated rats.

Authors:  Alfonso Alfaro-Rodríguez; Rigoberto González-Piña; Antonio Bueno-Nava; Emilio Arch-Tirado; Alberto Ávila-Luna; Rebeca Uribe-Escamilla; Javier Vargas-Sánchez
Journal:  Metab Brain Dis       Date:  2011-07-26       Impact factor: 3.584

3.  Efficacy and safety of levetiracetam in children with epilepsy: protocol for an umbrella review of systematic reviews and meta-analyses of randomised controlled trials.

Authors:  Jing Gan; Dan Ma; Tao Xiong
Journal:  BMJ Open       Date:  2019-07-10       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.